Peptide vaccine and peptide vaccine composition for cranial nerve disease

A peptide vaccine and cranial nerve technology, applied in the field of peptide vaccines and peptide vaccine compositions, can solve the problems of malignant transformation, peripheral nerve injury, and multiple tumors that cannot be actively operated on

Pending Publication Date: 2019-12-24
KEIO UNIV
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since the schwannomas of NF2 patients are hemorrhagic tumors, there is a high possibility that peripheral nerves will be damaged during surgery, and surgery cannot be performed aggressively especially for multiple tumors
In addition, although radiotherapy is also effective for smaller tumors, long-term control is often difficult, and there is also a risk of malignant transformation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peptide vaccine and peptide vaccine composition for cranial nerve disease
  • Peptide vaccine and peptide vaccine composition for cranial nerve disease
  • Peptide vaccine and peptide vaccine composition for cranial nerve disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0105] In Embodiment 1, the present invention provides a method for treating cranial nerve diseases, the method comprising: administering an effective amount of a peptide that induces CTL against VEGFR-1 expressing cells, or inducing CTL against VEGFR-2 expressing cells, to a patient in need of treatment. CTL peptides.

[0106] In Embodiment 1, the present invention provides a peptide that induces CTL against VEGFR-1 expressing cells or a peptide that induces CTL against VEGFR-2 expressing cells for treating cranial nerve diseases.

[0107] In Embodiment 1, the present invention provides the use of a peptide that induces CTL against VEGFR-1 expressing cells or a peptide that induces CTL against VEGFR-2 expressing cells for the manufacture of a therapeutic drug for cranial nerve diseases.

[0108] In each of these embodiments, the peptides that induce CTLs against VEGFR-1 expressing cells and the peptides that induce CTLs against VEGFR-2 expressing cells include the above-menti...

experiment example 1

[0112] (Preparation of Peptide Vaccine Composition)

[0113] 2 mg of the peptide comprising the amino acid sequence described in SEQ ID NO: 1, 2 mg of the peptide comprising the amino acid sequence described in SEQ ID NO: 5, and 1 mL of incomplete Freund's adjuvant (model "MONTANIDEISA51", SEPPIC Corporation ) were mixed to prepare an emulsion to prepare a 2 mL peptide vaccine composition.

experiment example 2

[0115] (Administration of the peptide vaccine composition to the patient of case 1)

[0116] The patient of Case 1 was a 30-year-old male. The HLA type of the patient in Case 1 was HLA-A*24:02. Bilateral vestibular schwannomas, trigeminal schwannomas, and meningiomas develop intracranially, and numerous schwannomas in the spinal cord or skin. He has no hearing on both sides and is bedridden. A total of 4 tumor resections and 3 gamma-knife irradiations including intracranial or spinal cord were performed, but it was difficult to control the growth of the tumor, and the tumor grew year by year. The peptide vaccine composition prepared in the same manner as in Experimental Example 1 was administered to the patient of Case 1.

[0117] (give schedule)

[0118] 1 mL of the peptide vaccine composition was subcutaneously administered each time around the bilateral axillary or inguinal lymph nodes of the patient. As the initial administration, for one month from the start of the a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A peptide vaccine for a cranial nerve disease is disclosed, said peptide vaccine comprising a peptide capable of inducing a cytotoxic T cell (CTL) to a cell expressing vascular endothelial growth factor receptor (VEGFR)-1 or a peptide capable of inducing a CTL to a cell expressing VEGFR-2.

Description

technical field [0001] The present invention relates to peptide vaccines and peptide vaccine compositions against cranial nerve diseases. This application claims priority based on Japanese Patent Application No. 2017-100361 for which it applied in Japan on May 19, 2017, and uses the content here. Background technique [0002] Neurofibromatosis type II (NF2), brain tumors, cerebrovascular diseases, autoimmune diseases, ophthalmic diseases, etc. are included in cranial nerve diseases. For example, NF2 is an autosomal dominant genetic disease caused by gene abnormality of the tumor suppressor merlin present in the long arm of chromosome 22, 22q12. The diagnosis of NF2 is determined by the occurrence of acoustic nerve tumors (precisely, vestibular schwannomas) on the left and right sides. Many tumors occur in NF2. Specifically, schwannomas occur in cranial nerves, spinal nerves, and peripheral nerves, and meningiomas, ependymomas, gliomas, and the like occur in the intracrani...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61P35/00A61P37/04
CPCA61K38/08A61K39/00A61P35/00A61P37/04C07K7/06A61K2039/55566A61K2039/70A61K39/001109
Inventor 户田正博田村亮太
Owner KEIO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products